0001562180-24-005567.txt : 20240703
0001562180-24-005567.hdr.sgml : 20240703
20240703075630
ACCESSION NUMBER: 0001562180-24-005567
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simpson Curran
CENTRAL INDEX KEY: 0001346164
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 241098264
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-07-01
false
0001590877
REGENXBIO Inc.
RGNX
0001346164
Simpson Curran
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
true
true
false
false
Chief Executive Officer
false
Common Stock
2024-07-01
4
A
false
56458.00
0.00
A
179785.00
D
Stock Options (Right to Buy)
11.07
2024-07-01
4
A
false
272189.00
0.00
A
2034-07-01
Common Stock
272189.00
272189.00
D
The restricted stock unit (RSU) award vesting commencement date shall be July 1, 2024. 1/4th of the shares subject to the RSU shall vest on each of the first, second, third and fourth anniversaries of the first day of the month in which the RSU was granted, subject to the continuous service of the recipient to the Issuer.
The option vesting commencement date shall be July 1, 2024. The options shall have a term of 10 years from the date of grant, subject to continuous service of the optionee to the Issuer. The options shall become exercisable as follows: with respect to 1/4th of the shares subject to the option when the optionee completes 12 months of continuous service to the Issuer after the vesting commencement date, and with respect to 1/48th of the shares subject to the option when the optionee completes each month of continuous service to the Issuer thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2024-07-03